Spleen tyrosine kinase (SYK) gene has been identified as novel susceptibility locus for ischaemic stroke (IS) previously. However, regulation of SYK gene remains unknown in IS. In this study, we aimed to identify miRNAs that might be involved in the development of IS by targeting SYK gene. miRNAs were firstly screened by bioinformatics predicting tool. The expression levels of SYK gene were detected by qRT-PCR and western blotting, respectively, after miRNA transfection. Luciferase reporter assay was applied to investigate the direct binding between miRNAs and target gene. miRNA levels were detected by miRNA TaqMan assays in the blood cells of 270 IS patients and 270 control volunteers. Results suggest that SYK gene might be a direct target of miR-129-2-3p. The blood level of miR-129-2-3p was significantly lower in IS patients (P < 0.05), and negatively associated with the risk of IS (adjusted OR: 0.88; 95% CI: 0.80-0.98; P = 0.021) by multivariable logistic regression analysis. The blood levels of SYK gene were significantly higher in IS patients, and miR-129-2-3p expression was negatively correlated with mean platelet volume.
and thrombosis. 3, 4 In addition to traditional risk factors, such as age, male sex, smoking, history of hypertension, diabetes mellitus and atrial fibrillation, amounting genetic risk factors have been identified in recent years by genome-wide association studies and exome sequencing. [5] [6] [7] [8] [9] [10] We have previously identified several susceptibility loci for IS in a Chinese Han population. 11 Exome sequencing was used to screen susceptibility loci among 100 cases and 100 matched controls. Significant SNPs were further verified in up to 3554 participants from three hospital-based case-control studies. Ultimately, we identified two novel loci (rs17118 of XYLB gene located on chromosome 3p21, and rs10489177 of c1orf156 gene located on chromosome 1q24), which were associated with an increased risk of IS. Besides, we also found that the frequency of rs2290890 T allele of spleen tyrosine kinase (SYK) gene was associated with a decreased risk of IS (data not published). SYK gene, located on chromosome 9p22
and encoding a non-receptor type of protein-tyrosine kinase, that is, widely expressed in hematopoietic cells, is one of the two members of the Syk family (Syk and ZAP-70), and has been extensively studied as a critical regulator in the pathogenesis of cancer. 12 SYK gene polymorphisms have been also reported to be associated with the risk of non-Hodgkin lymphoma 13 and prostate cancer. 14 Recently, the role of SYK in vascular inflammation and atherosclerosis has attracted great interest. In the low-density lipoprotein receptor-deficient mice consuming a high-cholesterol diet supplemented with orally available SYK inhibitor fostamatinib, the atherosclerotic lesion size was reduced by 59%, the adhesion and migration of inflammatory cells were attenuated, and macrophage survival was limited, suggesting SYK inhibition as a potentially fruitful anti-inflammatory therapeutic strategy in atherosclerosis. 15 In addition, Bijli et al suggested that Syk signals downstream of PKCdelta to mediate thrombin induced ICAM-1 expression in endothelial cells by increasing transcriptional capacity of NF-kappaB via a mechanism that relies on tyrosine phosphorylation of RelA/p65. 16 According to the literature review and our previous findings, we supposed that the dysregulation of SYK expression might be crucial for the development of IS, an atherosclerosis-related disease. However, no direct evidence has been reported about the expression and regulation of SYK in IS.
miRNAs are a class of 22-nucleotide-long endogenous non-coding RNAs which participate in the post-transcriptional regulation of genes by binding to the 3′ untranslated region (3′UTR). miRNAs are well recognized as key regulators in the pathological events of IS, including atherosclerosis, 17 hyperlipidemia, 18 hypertension 19 and plaque rupture. 20 Inspired by the clinical application of oral SYK inhibitors as previously indicated, 15 we further have been suggested that the decrease in SYK expression might be partially regulated by miRNA. To figure out the miRNAs that might target SYK expression and the miRNAs with potential clinical value as biomarker for IS, we firstly screened for miRNAs by the bioinformatics predicting tool 
| Target prediction and miRNA selection
The miRNAs that might target SYK gene were firstly predicted by in silico analysis using a bioinformatics tool: TargetScan (http://www.ta rgetscan.org/vert_71/). We previously explored the miRNA expression profiles of 25 IS patients and 25 control volunteers using miRNA microarray and found that 455 miRNAs were differentially expressed (unpublished data, P < 0.05). Ultimately, a total of 20 differentially expressed miRNAs with the most negative cumulative weighted context++ score by TargetScan Human 7.1 were selected for further investigation as shown in Table S1 . 
| Statistical analysis
The normal distribution of data was tested using the one-sample Kol- 3 | RESULTS
| Regulation of SYK expression by miR-129-2-3p
The microarray data and the cumulative weighted context++ scores of the 20 miRNAs were shown in Table S1 . Among the miRNAs, after transfection of miR-129-2-3p mimics for 48 hours, the mRNA level of SYK gene was both down-regulated in THP-1 and U937 cells, with a decreased level to 90% (THP-1) and 55% (U937) of the cells, respectively, compared with the mimic control ( Figure 1A) . However, the mRNA levels of SYK gene showed no alteration in cells transfected with other miRNA mimics ( Figure 1A and B). Afterwards, we evaluated the change in SYK protein levels after miR-129-2-3p transfection.
Results suggest that cells transfected with miR-129-2-3p mimics showed decreased protein levels of SYK in both THP-1 (to a 50% extent) and U937 cells (to a 40% extent), as shown in Figure 2A and B. 
| SYK expression in the blood cells of IS patients
To figure out the potential negative regulation of SYK by miR-129-2-3p, we further detected the mRNA levels of SYK in the blood cells of 60 IS patients and 60 control volunteers. Results suggested that the relative expression levels of SYK were significantly higher in IS patients compared with the control volunteers (log-transformed expression levels relative to beta-actin, −6.29 ± 0.85 vs −7.06 ± 0.92, P = 0.001), as shown in Figure 4B .
| Correlation between miR-129-2-3p expression and clinical parameters
Results of the correlation analysis between miR-129-2-3p expression and the clinical parameters suggest that the expression levels of miR-129-2-3p in blood cells were negatively correlated with the MPV level (r = −0.347, P < 0.001) in stroke patients, as shown in The motive that initiates the conduction of this study was the association that we found between SYK gene polymorphism and the risk of IS, which was identified by exome sequencing in one of our previous studies, 11 while not yet published. In recent years, studies safety. Therefore, the promise for the research and development of Syk inhibitor relies on the fact that the thrombosis is curtailed while haemostasis is preserved. 24 Proof of concept of the benefits of Syk inhibition in mouse models of thrombosis has been reported using small molecules 25, 26 or miRNA approach. 27 Van Eeuwijk, Nieswandt and colleagues reported a comprehensive approach to their proof of concept for the action of BI1002494 in IS. Results suggested that not only did pretreatment with BI1002494 reduce infract size without bleeding, but also administration of the inhibitor after the stroke was generated had similar benefits, providing a compelling case for continued investigation and translation of SYK inhibition strategy to human patients. 28 Inspired by our previous findings and the protec- and HUVECs (C) were cotransfected with luciferase constructs and mimic control/miR-129-2-3p respectively. After transfection for 24 hours, the relative luciferase activity was analysed by Dual-luciferase reporter system. Data were represented as mean ± SD from three independent experiments. ***P < 0.001 compared with the control groups analysed by one-way ANOVA validated our hypothesis that SYK expression might be negatively regulated by miR-129-2-3p. Moreover, our study is the first to that the sera level of miR-129-2-3p was decreased in patients with chronic congestive heart failure. 31 Collectively, the expression of miR-129-2-3p seems to be universally down-regulated in the pathological conditions, no matter in cancer or in cardiovascular diseases, suggesting a critical role of miR-129-2-3p in many pathological conditions. However, the role of miR-129-2-3p in stroke has been rarely reported. Interestingly, as we were preparing this manuscript, Tsai et al found that osteopontin could promote monocyte migration by upregulating IL-17 expression through miR-129-2-3p inhibition in osteoblast in rheumatoid arthritis disease. Notably, the Syk-dependent PI3K/Akt pathway also played a key role in osteopontininduced increase in monocyte migration and the decrease in miR-129-2-3p expression. 32 In the context of that, as we found in this study that SYK expression could also be regulated by miR-129-2-3p, it seems that there might be a reciprocal regulation circle between miR-129-2-3p and Syk, which needs further investigation.
Platelets are small cell fragments in the blood. The classical function of platelets is coverage and closure of endothelial wounds, and contact between platelets and the subendothelial matrix triggers their activation and drives thrombus formation. Platelet activation can confer pro-atherosclerotic effects, and plays critical roles in the development of atherosclerosis and cardiovascular diseases. 33 MPV is a useful biomarker for platelet activity. O'Malley et al noticed an increase in MPV in all subtypes of IS. 34 This increase was already detectable in the acute phase (within 48 hours of the onset of symptoms) and persisted long after the stroke (the second measurement was performed after 6 months). This finding led to the conclusion that increased MPV values were probably pre-existent to the acute event, and were potentially involved in the genesis of the disease, considering, in particular, that mean platelet life is only 8 days.
Besides, MPV can even provide some information about the prognosis of stroke patients. 35 In this study, we found that the MPV levels of IS patients were significantly higher than the control volunteers and the decreased level of miR-129-2-3p was negatively correlated with MPV in the stroke patients ( Figure 5 ). Several platelet functions rely on SYK signaling. GpVI, the major collagen receptor of platelets, is an FcRγ-associated receptor closely related to FcαRs, which may explain that GpVI, like other FcR family members, signals through SYK. 36 The C-type lectin CLEC2 has also been shown to signal through SYK in platelets. 37 Taken together, we conclude that the underlying mechanism for miR-129-2-3p in IS may involve activation of the platelet function by regulating the Syk-GpVI signaling pathway, which needs further investigations about the underlying mechanism.
This study has several strengths. First, the expression level of miR-129-2-3p was detected in a case-control population with comparatively large sample size, providing sufficient statistical power for multivariate analysis. We calculated the statistical power using the tool PASS. This study has 86% power to detect convincing associa- 
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Correlation between miR-129-2-3p expression and the platelet parameter. Correlation between miR-129-2-3p expression and the mean platelet volume was analysed by Pearson's correlation test in stroke patients
The expression levels of miR-129-2-3p and SYK gene in IS patients and control volunteers. (A) miR-129-2-3p expression was detected in the whole blood of 270 ischaemic stroke patients and 270 control volunteers. The relative expression levels were normalized to U6 and then log-transformed. (B) The expression levels of SYK gene were detected in the whole blood of 60 ischaemic stroke patients and 60 control volunteers. The relative expression levels were normalized to beta-actin and then logtransformed. The whiskers of the plots represent the 5-95 percentiles. Comparison of gene expression between the two groups of cohorts was analysed by the Student's t test both exist in stroke genetics, 40 accumulating evidence to explore the functional SNPs associated with stroke have been reported recently, by means of eQTLs. 41, 42 Inspired by the above studies, we will further combine in silico and experimental approaches to explore the functional SNPs of SYK gene, which might improve our understanding of disease mechanism in stroke and likely provide the field with novel targets and pathways for intervention.
In summary, this study suggests that the blood cell level of miR-129-2-3p is significantly lower in IS patients and associated with the occurrence of IS. SYK gene might be a direct target of miR-129-2-3p, and the expression levels of SYK gene were significantly higher in IS patients compared with control volunteers. In addition, miR-129-2-3p expression was negatively correlated with the platelet parameter MPV. Further investigations are needed to explore the biological relevance of our findings.
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